Lupin rises on launching first generic version of Oracea in United States
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 1627.95, up by 22.90 points or 1.43% from its previous closing of Rs. 1605.05 on the BSE.
The scrip opened at Rs. 1633.25 and has touched a high and low of Rs. 1644.20 and Rs. 1625.00 respectively. So far 7867 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 655.75 on 17-Apr-2023.
Last one week high and low of the scrip stood at Rs. 1644.20 and Rs. 1583.10 respectively. The current market cap of the company is Rs. 73140.57 crore.
The promoters holding in the company stood at 47.04%, while Institutions and Non-Institutions held 45.84% and 7.11% respectively.
Lupin has launched first generic version of Oracea (Doxycycline Capsules, 40 mg), in the United States, after having received an approval from the United States Food and Drug Administration (USFDA). Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Doxycycline Capsules had estimated annual sales of $128 million in the U.S. (IQVIA MAT February 2024).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
